Aurinia Pharmaceuticals (AUPH) PT Raised to $11 at RBC Capital
Tweet
Share
E-mailGet Alerts AUPH Hot Sheet
Price: $16.65 -1.48%
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 25
Rating Summary:
6 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 9 | Down: 6 | New: 25
Join SI Premium – FREE
RBC Capital analyst Douglas Miehm raised the price target on Aurinia Pharmaceuticals (NASDAQ: AUPH) to $11.00 (from $9.00) while maintaining a Outperform rating.
- no surprises out of the results
- remains on track in its Ph. III lupus nephritis trial
- updated model on positive IP developments for voclosporin
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teradata (TDC) PT Lowered to $32 at UBS on Cautious Q3 View
- RBC Capital Upgrades Telix Pharmaceuticals Ltd (TLX:AU) (TLX) to Outperform
- Brinker Int'l (EAT) PT Lowered to $210 at DA Davidson as Same Store Sales Expected to Normalize
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT ChangeRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
